HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Ephedra Found, Sibutramine Crime In Texas: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

MusclMasster recalls Al-Er-G after FDA officials discovered during a recent inspection it contained ephedra. The use of sibutramine in products marketed as supplements led to a Texas man's conviction on a criminal count of possessing a controlled substance.

You may also be interested in...



Sibutramine-Spiked Supplements: Consumer Health Product Recall News

The latest product marketed as a dietary supplement but containing the banned weight loss ingredient sibutramine is A1 Slim, on recall by Kiriko. Three flavors of Jete Nutritional Energy Bar were recalled due to labeling errors, including omitting that sulfites in the products came from Non-GMO apples.

Hi-Tech CEO Wheat Arrested In FDA Investigation Of Steroid-Spiked Supplements

Hi-Tech Pharmaceuticals CEO Jared Wheat and an associate face 18 criminal charges in federal court alleging they falsified FDA documents and distributed as supplements products containing steroid ingredient. Wheat is appealing the indictment to federal circuit court.

GMP, Claim And Label Warning Follows Firm's Ephedra Recall

FDA Office of Regulatory Affairs' warning letter to MusclMasster lists 12 separate violations of supplement GMP regulations. Puerto Rico firm is latest supplement own-labeler to receive GMP warnings.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel